

SOME NEWER APPROACHES TO THE PROBLEMS OF ARTERIOSCLEROSIS

PART II - EXPERIMENTAL THERAPEUTIC APPROACH TO THE PROBLEMS OF ATHEROMATOSIS

GEORGE R. HERRMANN *

Herbivorous animals such as rabbits and guinea pigs were found to be easily susceptible to atheromatosis following the feeding of cholesterol. Cats and dogs until recently were found refractory. Fox ¹ discovered that birds developed spontaneously with advancing age, atherosclerosis closely resembling that found in humans. Dauber ² emphasized the great frequency with which aortic atheroma were present in chickens over 6 months of age. We demonstrated in our laboratory high blood and tissue total cholesterol and cholesterol esters in old hens, especially in the high egg producing (Texas A. and M.) white leghorn stock. It would seem, therefore, that omnivorous domestic fowl of this type would be a most suitable animal for the study of spontaneous atherosclerosis. Chickens normally ingest animal cholesterol-containing foods. We chose three year old white leghorn hens for the study of the effects of decholesterolemia and atheromatosis. Young pullets and cockerels were chosen from the same stock for the study of the effect of these agents on experimentally induced hypercholesterolemia and atheromatosis in the tissues.

Anitschkow ³ demonstrated that the feeding of cholesterol in oil to rabbits produced marked atherosclerotic changes. Murata and Kataoka ⁴ in 1918 discovered that the administration of thyroid extract along with the cholesterol prevented the atheromatosis of the aorta. This was confirmed by Liebig ⁵. Turner and Khayat, and Meeker, Kesten and Jobling ⁶ found that potassium iodide prevented the usual hypocholesterolemia in aortic atheromatosis in normal animals fed cholesterol. If the thyroid gland was removed the potassium iodide did not have its prophylactic action. Page and Bernhard ⁷,^a noted that administration of di-iodide of ricinsterolic acid decreased atheromatosis

* M.D., Ph. D., Professor of Medicine, University of Texas Medical School, Galveston, Texas, U.S.A.

but actually caused elevation of the blood cholesterol suggesting a tissue receptivity factor. Eberhard ^{7.b} found that alcohol fed to rabbits along with cholesterol produced greater hypercholesterolemia but less atheromatosis. Bruger et al.⁸ found that sex hormones inhibited hypercholesterolemia and atheromatosis in normal female rabbits fed cholesterol but not after castration. Duff and McMillan found that the alloxan diabetes in spite of hyperlipemia limited sharply the atheromatosis in cholesterol fed rabbits.

Allan and his associates ⁹ discovered the beneficent effects of feeding of fresh pancreas in the clearing and prevention of fat deposition in the liver of depancreatized dogs. Fisher ¹⁰ demonstrated the effectiveness of dried pancreas, Hershey ¹¹ used crude lecithin for the same purpose, Chaikoff and Kaplan ¹² prepared a litotropic fraction AR extract of the pancreas which they found had lipotropic properties. Dragsted et al. ¹³ named his extract "lipocaic" and Wolffe et al. ¹⁴ called his extract "lipolysin". Best and Huntsman's ¹⁵ selection of choline as the lipotropic factor initiated many further and generally confirmatory studies. Huber, Broun and Casey ¹⁶ found that the lipocaic was effective in the prevention of deposition of lipids in the aortic subintima of rabbits fed cholesterol. Kersten and Silbowitz ¹⁷ reported that soya lecithin similarly delayed but did not prevent hypercholesterolemia and atheromatosis in rabbits.

Our *experimental results* with choline, methionine and inositol on naturally occurring hypercholesterolemia and subintimal atheromatosis

EFFECTS OF CHOLINE INOSITOL AND METHIONINE ON BLOOD TISSUE LIPIDS

	Blood cholesterol mg/100ml		Livid PO ₄	Tissue cholesterol mg/100					
	Total	Esters		Aorta		Heart		Liver	
				Total	Esters	Total	Esters	Total	Esters
Control series 36 old mens	274 8 SD± 39	166 ± 19	06 ± 27	230 ± 41	1762 ± 204	275 ± 71	223 ± 19	340 ± 65	240 ± 24
Choline 20 3&A 28-72 days	174 SD± 25	121 ± 108		190 ± 292		205 ± 203		236 ± 93	
Choline 26 W&S 10-64 days	179 SD ± 24	144 ± 92	101 ± 18	165 ± 50	83 ± 24	198 ± 57	147 ± 19	249 ± 57	210 ± 256
Control series 20 old mens	195 SD ± 18	147 ± 20	107 ± 2	253 ± 50	188 ± 47	233 ± 48	172	303 ± 50	223 ± 38
Inositol 23 30-68 days	184 SD ± 19	135 ± 16	118 ± 19	201 ± 38	155 ± 44	166 ± 37	129	253 ± 55	191 ± 43
Methionine 23 36-57 days	138 SD ± 25	95 ± 24	166 ± 4	156 ± 21	102 ± 21	135 ± 19	91 ± 13	276 ± 94	169 ± 63

S.D. Standard Deviation S&A Summer & Autumn W&S Winter & Spring

Table 1 - Hypercholesterolemia and the effects of lipopropic agents in old hens. The data in these tables were assembled and statistically treated by John W. Chriss, M.D. and Paul M. Sims, M. D. Fellows in Cardiovascular Research under the H. H. Weinert Fund.

in old hens, Texas A. & M. white leghorn, high producing stock, may be shown in Table 1. In comparison with the two series of 26 old hens control, the 26 old hens placed on choline chloride 0.5 gram daily, showed some reduction of the cholesterol levels of the blood in the aorta, heart muscle, and liver. A similar series of 3-year old hens given 0.5 gram of inositol, showed less but still some decholesterolizing effect. In other series of the same stock, methionine 0.4 gram dose, had seemingly considerable decholesterolizing effect.

It was found that young birds of the same Texas A. & M. white leghorn stock at growing mash, impregnated with cholesterol in oil, in preference to the mash itself. They were started on doses of 0.5 gram a day in 5 cc. cotton seed oil, showing rapid rises and high lipid levels until about the 40th day, and grew normally. The cholesterol level dropped off some in most birds. After 40 days of treatment of cholesterol in oil, all birds showed gross evidences of atheromatosis in the aorta coronaries. The livers were also very fatty. All the tissues had increased contents of cholesterol and cholesterol esters. The control series and various experimental studies are shown in Tables 2, 3, 4 and 5. In these series, after about 40 days we halved the dose of cholesterol to 0.5 grams in 5 cc. of oil every other day. This brought the blood levels down to a third of what they had been. The addition of 0.5 gram of inositol or 0.5 gram choline and 2 cc. Kumbacha was apparently not significant when given from the beginning.

**BLOOD AND TISSUE STUDIES ON YOUNG COCKERELS
FED CHOLESTEROL AND VARIOUS DECHOLESTERIZING AGENTS**

Group	Treat.	Days	Blood Total Esters		Treat. Days	Change Drug	Final Total	Blood Esters	Heart Total Esters	Liver Total Esters	Aorta Total Esters		Grade		
F-6	Cholest 0.5/D	44	1579 ±407	264 ±510	112	No Cholest Inositol 0.5/D	175 ±65	75 ±60	356 ±67	103 ±75	800 ±67	203 ±52	602 ±108	254 ±141	0
G-6	Cholest 0.5/D	44	1632 ±241	1225 ±338	114	No Cholest Kumbacha 0.5/D	170 ±31	60 ±26	314 ±62	97 ±35	1028 ±547	205 ±154	648 ±241	407 ±275	0
H-6	Cholest 0.5/D	44	1395 ±417	1001 ±478	114	No Cholest Choline 0.5/D	169 ±38	71 ±11	273 ±107	78 ±48	612 ±209	253 ±188	342 ±133	156 ±64	0
I-5	Cholest 0.5/D	44	1604 ±406	1291 ±507	116	No Cholest No Drug	143 ±26	61 ±11	324 ±37	128 ±82	878 ±12	193 ±84	447 ±101	173 ±68	0
J-5	Cholest 0.5/D	44	1207 ±194	1398 ±242	108	No Cholest No Drug	159 ±18	65 ±16	303 ±55	75 ±23	748 ±93	305 ±24	565 ±80	137 ±84	7 17
K-14	Cholest 0.5/D	46	1400 ±280	991 ±343	112	No Cholest No Drug	155 ±24	59 ±14	334 ±42	103 ±56	810 ±109	218 ±30	453 ±61	164 ±55	0

Table 2

In three other groups the addition of the drugs after the discontinuance of the cholesterol feeding on the 44th day seemed to have no definite effect on the return to normal levels in the blood and tissues in 70 days of treatment. The cholesterol levels in the tissues were still high after the decholesterolizing agents were used, with the exception of the series in which choline was used, were brought to the normal. Four other series, in which the cholesterol 0.5 gram in 5 cc. of corn oil daily was maintained, one given no drug, another given 2.5 gram daily choline, another 2.5 gram

**BLOOD AND TISSUE STUDIES ON YOUNG COCKERELS
FED CHOLESTEROL & VARIOUS DECHOLESTERIZING AGENTS**

Group	Treat	Days	Blood		Treat Days	Change Drug	Final Blood		Heart		Liver		Aorta		Grade
			Total	Esters			Total	Esters	Total	Esters	Total	Esters			
L-25	Chol 0.5 gm Day	56	589 ±285	330 ±189	68	0	525 ±190	257 ±133	480 ±77	290 ±83	3820 ±1002	2320 ±1462	690 ±486	210 ±234	i-ii
M-12	Chol 0.5 gm Choline 2.5 gm	66	379 ±102	184 ±92	77	0	395 ±157	171 ±97	403 ±67	176 ±86	2389 ±968	1148 ±650	579 ±176	171 ±127	0
N-10	Plain Food only	56	219 ±28	68 ±18	78	0	172 ±41	57 ±32	368 ±90	126 ±78	754 ±187	209 ±114	340 ±43	66 ±49	0
O-12	Chol 0.5/0 maistol 2.5 CM	66	326 ±10	134 ±104	74	0	359 ±157	142 ±96	393 ±58	212 ±86	1931 ±1006	1003 ±798	428 ±152	170 ±72	i
P-13	Cholest 0.5/0 Choline 2.5 gm maistol 2.5 gm	72 74 78			76	0	460 ±98	209 ±184	433 ±111	177 ±91	2630 ±1730	1207 ±777	598 ±176	191 ±86	i

Table 3

**BLOOD AND TISSUE STUDIES ON YOUNG COCKERELS
FED CHOLESTEROL & VARIOUS DECHOLESTERIZING AGENTS**

Group	Treat	Days	Blood		Treat Days	Change Drug	Final Blood		Heart		Liver		Aorta		Grade
			Total	Esters			Total	Esters	Total	Esters	Total	Esters			
A-20	Greenz	48	214 ±57	87 ±47	68 to 112	No Drug Control	175 ±35	40 ±27	386 ±179	134 ±69	749 ±196	241 ±163	454 ±163	166 ±72	0 in all
B-20	Greenz Chol 0.5 gm	40	968 ±512	577 ±435	66 to 112	Cholest 0.5 q 5/0	324 ±114	122 ±96	715 ±315	449 ±207	1890 ±1199	992 ±825	1113 ±555	640 ±394	i-iii
C-10	Cholest 0.5 gm maistol 0.5 gm	40	1193 ±470	804 ±465	67	Chol 0.5 1/0	485 ±314	248 ±212	692 ±266	443 ±104	1575 ±1008	978 ±1108	1243 ±413	798 ±561	i-ii
D-10	Chol 0.5/0 Kambacho 20 cc/0	40	1435 ±460	920 ±401	67	Chol 0.5 1/20	446 ±322	224 ±118	847 ±234	592 ±224	1072 ±664	1178 ±677	1653 ±506	1140 ±362	i-ii
E-10	Cholest 0.5/0 Choline 0.5/0	40	1502 ±459	1047 ±400	70	Chol 0.5 q 20	442 ±155	167 ±85	684 ±178	440 ±31	1604 ±430	865 ±208	1292 ±282	826 ±214	i-ii
F-6	Cholest 0.5/0	40	1579 ±407	1264 ±519	112 -68 off	Chol maistol 0.5/0	175 ±65	75 ±60	356 ±67	103 ±75	800 ±67	203 ±52	602 ±198	254 ±141	0

Table 4

daily inositol, the combination of the two drugs and a group of controls on plain food, showed lower values in general in the blood and in the tissues of those on drugs, but the standard deviations were too high.




Table 5

HUMAN STUDIES

Pathologists and clinicians long ago learned that in certain types of patients atheromatosis was an unusually common occurrence and frequently the cause of death. Atheromatous pathological process was often found in strategic arteries in patients who had died suddenly with cardiac pains, angina pectoris, had hypertension, aortic sclerosis with hypotension and metabolic disease as diabetes mellitus, nephrosis, or nephritis. In certain intoxications in patients, the possibilities of atheromatous complications are recognized. Clinicians have tried to identify the factors which contributed to the development of atherosclerosis, and efforts were made to control the factors. There seemed to be no single common denominator, no single factor. The prevention of mechanical strain, and a lowering or a raising of the blood pressure as indicated. Hueper¹⁸ felt that the permeability of the intima to plasma lipids was the chief factor but hypercholesterolemia seems to the clinician to be very important, if not the most important, readily attackable, factor.

In the past few years, we have carried out extensive blood chemical studies, particularly for the total cholesterols, cholesterol esters, and sometimes for the plasma, phosphate lipid levels in normal individuals and from several groups of patients with chronic medical conditions. The results are tabulated in tables 6, 7 and 8. This study has impressed upon us the fact that hypercholesterolemia is an important predisposing factor. Since hypercholesterolemia is a factor we may attack or study it in patients while treating the primary disease process. We know that hypercholesterolemia of diabetes mellitus disappears on adequate insulin therapy and that of myxedema responds to

**BLOOD TOTAL CHOLESTEROL E CHOLESTEROL ESTERS
IN KNOWN ARTERIAL DISEASE CASES**

Under 50 yrs Total Mg % Over 50 yrs Total Mg % Esters Mg % Total Cases

ATHER CAD CO-MI-AP	78	295 SD ± 64	202 ± 54	85	292 ± 66	193 ± 51	263
ATHER AORTITIS	55	296 ± 81	199 ± 64	142	291 ± 75	190 ± 54	197
HIPERTENSION	98	262 ± 61	175 ± 51	167	276 ± 89	189 ± 68	265
NO VASC DISEASE	168	225 ± 58	152 ± 45	72	252 ± 70	161 ± 50	240

Table 6

BLOOD LIPIDS IN MISCELLANEOUS CONDITIONS

	Cholesterol				Cholesterol		
	Under 50 yrs	Total Mg % Esters	Mg %	Over 50 yrs	Total Mg % Esters	Mg %	Total Cases
CHOLECYSTITIS	48	274 SD + 78	169 ± 68	29	304 ± 135	178 ± 99	77
CIRRHOSIS	28	220 ± 56	142 ± 49	43	225 ± 55	150 ± 45	71
SYPHILIS LATENT	14	218	141 ± 39	10	257 ± 50	163 ± 48	24
TUBERCULOSIS	16	214 214± 48	152 ± 50	7	250 ± 41	169 ± 21	23
RHEUMATIC H.D.	31	226 ± 47	140 ± 39	9	277 ± 57	177 ± 34	40

Table 7

BLOOD LIPIDS IN METABOLIC THAT SHOW A.S.

	Cholesterol				Cholesterol		
	Under 50 yrs	Total Mg % Esters	Mg %	Over 50 yrs	Total Mg % Esters	Mg %	Total Cases
DIABETES	40	277 ± 98	188 ± 80	69	277 ± 98	173 ± 50	109
NEPHRITIS E NEPHROS'S	27	436 ± 324	296 ± 253	10	337 ± 150	222 ± 159	37
HYPOTHYROID	26	304 ± 111	200 ± 63	15	311 ± 103	200 ± 88	41
HYPERTHYROID	33	208 ± 38	128 ± 43	9	239 ± 45	176 ± 53	42
C.A.	26	236 ± 59	153 ± 42	45	224 ± 61	146 ± 43	71

Table 8

adequate thyroid extract administration. Beyond that, our therapy must be based upon our results in experimental animal studies and empiricism. The use of potassium iodide and potassium thiocyanate in hypertensive patients, and sex hormones in otherwise normal adults, are still in the experimental stage of the use of all decholesterolizing agents. The experimental results that we have observed with choline and inositol, are not as encouraging as those reported with lipocaic. We have had no results with soya lecithin, Kumbacha and other preparations on the hypocholesterolemia and atheromatosis.

There is no more practical, direct approach to the problem in humans than the therapeutic trial method. During the past two years, patients with high blood cholesterol level have been put on low cholesterol diet and given potassium iodide, thyroid extract, and various lipotropic substances that we had used in the experimental studies. The levels of the blood were determined at intervals from 3 to 6 months. Choline, chloride, bicarbonate, and dihydrogen citrate, and inositol were used and the results are given in Table 9.

EFFECT OF TREATMENT OF HYPERCHOLESTEROLEMIA

No of cases	drug treatment	Cholesterol		% Change in Relation to deviation from Normal	
		Total	Esters		
BI CHOLINE	Before ^c Chloride	306	222	53%	46%
	After	273	188		
	% Drop	14.3%	17.1%		
9 CHOLINE	Before ^c HCO ₃	385	240	53%	54%
	After	309	173		
	% Drop	19.9%	23.9%		
17 CHOLINE	Before ^c DihCr	304	220	70%	57%
	After	256	165		
	% Drop	20.5%	19.1%		
39 CHOLINE	Before i-inox	325	198	40%	38%
	After	286	185		
	% Drop	10.7%	14.8%		
20 SOYALECITHIN	Before ^{acletin}	322	206	13%	24%
	After ^{Granulestia}	308	191		
	% Drop	2.3%	6.5%		

TABLE 9

The patients who were placed on a low cholesterol diet, potassium iodide alone, showed no significant reduction. After 6 to 12 months, the patients with thyroid extract were more definitely affected. No more cases have been studied than previously reported and these were too few to be significant. The same may be said for the cases receiving methionine. Choline and inositol have been used more extensively. Only such patients with initially very high levels were included. The percentage changes are not very great although the cholesterol and esters reductions amounted to 10-20%. The percentage changes calculated in relation to the deviation from normal and a return toward normal showed 50-70%. These latter figures are somewhat encouraging. A completely satisfactory decholesterolizing agent however has not yet been found. The specific hormone has not been discovered. Little is known of the intermediary metabolism of cholesterol, its syn-

thesis, transport or catabolism. The enzyme system responsible for the degradation of cholesterol has not yet been elucidated. There may be some significance to the level of blood serum albumin "fraction (Cohn)" which showed a high titre of antilipofanogens (Simms and Pashley¹⁹). The permeability of the intima, the internal receptivity of the subintimal tissues may play important roles.

Maintenance of the colloid equilibrium and prevention of altered precipitability of the lipids must be the goal of treatment. Whether thyroid extract, potassium iodide, choline and inositol affect the formation of atheromatous lesions in humans as in animals is not known. Once the atheromatous plaque has developed, its recession, as apparently happens in animal experiments, is hoped for, but we should continue to seek methods of therapy that will alter or remove the contributory conditions.

The attack on the age-old problem of atherosclerosis must continue and new methods of attack must be evolved with the new isotope tools. In the meantime, we must continue to be patient and prosecute the studies with the means that we now have available. Much more difficult and extensive longterm experimental studies, including absolute and relative quantities of blood lipids and serum protein fractions, identification of sources of lipofanogens and antilipofanogens, cholesterololytic agents, status of intracellular and intercellular colloids, as to aggregation and water binding power, vibratory lability, colloid stability, of lipid substance, detergents or substances increasing the permeability of the intima and the receptivity of the subintimal tissues, calcium, oxygen, CO oxidases, phosphatases and lipases levels must be done. We must be content² with small rewards until the problem is solved. The metabolic disorders must be corrected before the destructiveness of the atheromatosis processes and advances to the point of contributing to this final and fatal phase. We may stay the execution and post-pone the premature pathological aging and normal physiological aging of senescence and senility.

REFERENCES

1. Fox, H. - Arteriosclerosis in Wild Mammals and Birds. Bull. N.Y. Acad. Med, 15:748, 1939.
2. Dauber, D. V. - Spontaneous arteriosclerosis in chickens. Arch. Pathol., 38:46, 1944.
3. Anitschkow, N. - Experimental studies of arteriosclerosis. Verhandl. d. deutsch. Gesellsch. f. inn. Med, 20:149, 1923.
4. Murata, M. and Kataoka, S. - Experimentelle Arteriosklerose und Schilddrüsenfütterung. Tr. Jap. Pathol, 8:221, 1918.
5. Liebig, H. - Die Beeinflussung der experimentelle Atherosklerose durch Jodbehandlung. Arch. f. exper. Pathol. u. Pharmakol, 159:265-274, 1931.

6. a) Turner, K. B. and Khayat, G. B. - Studies on the prevention of cholesterol atherosclerosis in rabbits. *J. Exper. Med*, 53:127-135 (July) 1933; b) Meeker, D. R., Kesten, H. D. and Jobling, J. W. - Effect of iodine on cholesterol-induced atherosclerosis. *Arch. Pathol*, 20:337-342, 1935.
7. a) Page, I. H. and Bernhard, W. B. - Cholesterol-induced atherosclerosis, its prevention in rabbits by feeding of organic iodine compounds. *Arch. Pathol*, 19:530-536, 1935, b) Eberhard, T. P. - Effect of alcohol on cholesterol-induced atherosclerosis in rabbits. *Arch. Pathol*, 21:616-627, 1936.
8. Bruger, M., Wright, I. S. and Wiland, J. - Experimental atherosclerosis; effect of testosterone propionate and estradiol dipropionate on cholesterol content of blood and aorta in castrate female rabbits. *Arch. Pathol*, 86: 612-614, 1943.
9. Allan, F. N., Bowie, D. J., MacLeod, J. J. R. and Robinson, W. - Behaviour of depancreatized dogs kept alive with insulin. *Brit. J. Exper. Pathol*, 5:75-83, 1924.
10. Fisher, N. F. - Attempts to maintain life of totally depancreatized dogs indefinitely by insulin. *Am. J. Physiol*, 67:634-643, 1924.
11. Hershey, J. M. - Substitution of lecithin for raw pancreas in the diet of the depancreatized dog. *Am. J. Physiol*, 93:657-658, 1930.
12. a) Chaikoff, I. L. and Kaplan, A. - Influence of ingestion of raw pancreas upon blood lipids of completely depancreatized dogs maintained with insulin. *J. Biol. Chem*, 112:115, 1935, b) Chaikoff, I. L. and Kaplan, A. - Distribution of fat in livers of depancreatized dogs maintained with insulin. *J. Biol. Chem*, 119:423, 1937; c) Perlman, I. and Chaikoff, I. L. - Radioactive phosphorus as indicator of phospholipid metabolism; on mechanism of action of choline upon liver of fat-fed rats. *J. Biol. Chem*, 127:211, 1939; d) Perlman, I., Stillman, N. and Chaikoff, I. L. - Radioactive phosphorus as indicator of phospholipid metabolism; influence of methionine, cysteine and cysteine upon phospholipid turnover in liver. *J. Biol. Chem*, 133:651, 1940; e) Friedlander, H. D., Chaikoff, I. L. and Enterman, C. - Effect of ingested choline on turnover of plasma phospholipids. *J. Biol. Chem*, 158:231, 1945.
13. Dragstedt, L. R., van Prohaska, J. and Harms, H. P. - Observations on substance in pancreas (fat metabolizing hormone) which permits survival and prevents liver changes in depancreatized dogs. *Am. J. Physiol*, 117:175-181, 1936.
14. Wolffe, J. B. et al. - Present status of lipocaic (Preliminary report of the Council on Pharmacy and Biochemistry). *I.A.M.A*, 115:1454-1455 (October 26) 1910.
15. a) Best, C. H., Hershey, J. M. and Huntsman, M. E. - Effect of lecithine on fat deposition in liver of normal rat. *J. Physiol*, 75:56-66 (May) 1932; b) Best, C. H. and Huntsman, M. E. - Effects of components of lecithine upon deposition of fat in liver. *J. Physiol*, 75:405-412 (August) 1932.
16. Huber, M. J., Broun, G. O. and Casy, A. E. - Prevention of cholesterol arteriosclerosis in rabbit by use of pancreatic extract (lipocaic). *Proc. Soc. Exper. Biol. a. Med*, 37 441-445, 1937.
17. Kesten, H. D. and Silbowitz, R. - Experimental atherosclerosis and soya lecithin. *Proc. Soc. Exper. Biol. a. Med*, 49:71-73, 1942.
18. Hueper, W. C. - a) Arteriosclerosis and atheromatosis. *Medicine*, 20: 397, 1941; b) Arteriosclerosis; a general review. *Arch. Pathol*, 38:162, 245, 350, 1944; c) *Arch. Pathol*, 39:51, 117, 187, 1945.
19. Simms, H. S. and Pashley, M. S. - Studies in fat depositing mechanisms.